Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Bolt Biotherapeutics, Inc. - Common Stock (NQ:BOLT)

5.920 +0.010 (+0.17%)
Streaming Delayed Price Updated: 1:00 PM EDT, Jul 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Bolt Biotherapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
Bolt Biotherapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
From Bolt Biotherapeutics, Inc.
Via GlobeNewswire
Bolt Biotherapeutics Announces Positive Topline Data from BDC-1001 Phase 1 Dose-Escalation Trial in HER2-Expressing Tumors, Supporting Advancement to Phase 2 Clinical Studies
From Bolt Biotherapeutics, Inc.
Via GlobeNewswire
Bolt Biotherapeutics to Present Preclinical Data for BDC-3042, a Dectin-2-Targeting Agonistic Antibody, at 2023 AACR Annual Meeting
From Bolt Biotherapeutics, Inc.
Via GlobeNewswire
Stocks That Hit 52-Week Lows On Friday
During Friday's morning session, 234 stocks hit new 52-week lows. Interesting Facts About Today's 52-Week Lows: The largest company in terms of market cap... 
Via Benzinga
Bolt Biotherapeutics to Present at Cowen 43rd Annual Healthcare Conference
From Bolt Biotherapeutics, Inc.
Via GlobeNewswire
Bolt Biotherapeutics to Present at February Investor Conferences
From Bolt Biotherapeutics, Inc.
Via GlobeNewswire
Bolt Biotherapeutics Appoints Laura Berner to Board of Directors
From Bolt Biotherapeutics, Inc.
Via GlobeNewswire
Bolt Biotherapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update
From Bolt Biotherapeutics, Inc.
Via GlobeNewswire
Bolt Biotherapeutics to Present Preclinical Data on BDC-3042, Dectin-2 Targeting Agonistic Antibody, at the SITC Annual Meeting
From Bolt Biotherapeutics, Inc.
Via GlobeNewswire
Bolt Biotherapeutics to Present at Stifel 2022 Healthcare Conference
From Bolt Biotherapeutics, Inc.
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For August 11, 2022
  
Via Benzinga
SVB Leerink Cuts Price Target On This Stock By 50%, Also Check Out Some Other Major PT Changes
SVB Leerink cut the price target on Bolt Biotherapeutics, Inc. (NASDAQ: BOLT) from $8 to $4. SVB Leerink analyst Daina Graybosch downgraded the stock from Outperform to Market Perform. Bolt... 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers NeuroBo Pharmaceuticals (NASDAQ:NRBO) shares increased by 15.1% to $0.63 during Wednesday's after-market session. The company's market cap stands at $16.7 million. 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Bolt Biotherapeutics's Return On Capital Employed Overview
Bolt Biotherapeutics (NASDAQ:BOLT) brought in sales totaling $508.00 thousand during Q4 according to data provided by Benzinga Pro. However, earnings decreased 16.08%, resulting in a loss of $27.16... 
Via Benzinga
This Low-Float Stock Jumps Around 148%; Here's 64 Biggest Movers From Yesterday
Gainers United Maritime Corporation (NASDAQ: USEA) climbed 147.6% to close at $7.08 on Thursday on heavy momentum following the company's recent listing on the Nasdaq Capital Market. 
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Soleno Therapeutics (NASDAQ:SLNO) shares rose 15.7% to $0.37 during Monday's pre-market session. The market value of their outstanding shares is at $29.5... 
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
On Wednesday, 160 companies hit new 52-week lows. Areas of Significance In Today's 52-Week Lows: Walt Disney (NYSE:DIS) was the largest firm by market cap to set a new... 
Via Benzinga
7 Little-Known Penny Stocks That Could Take Off Any Moment
Penny stocks are incredibly risky and should only be considered with speculation funds. Still, these names could swing higher for investors. 
Via InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For January 6, 2022
Upgrades For Canada Goose Holdings Inc (NYSE: 
Via Benzinga
60 Biggest Movers From Yesterday
Gainers Insignia Systems, Inc. (NASDAQ: ISIG) shares jumped 200.4% to close at $15.05 on Monday after the company announced the commencement of a formal process to explore... 
Via Benzinga
Mid-Afternoon Market Update: Dow Jumps 700 Points; Del Taco Restaurants Shares Spike Higher
Toward the end of trading Monday, the Dow traded up 2.11% to 35,308.84 while the NASDAQ rose 1.24% to 15,272.25. The S&P also rose, gaining 1.51% to 4,607.08. The U.S. has the... 
Via Benzinga
Topics Stocks
Mid-Day Market Update: Crude Oil Rises 3%; Aeglea BioTherapeutics Shares Plunge
Midway through trading Monday, the Dow traded up 1.94% to 35,251.31 while the NASDAQ rose 0.55% to 15,168.35. The S&P also rose, gaining 1.20% to 4,592.83. The U.S. has the... 
Via Benzinga
Topics Stocks
36 Stocks Moving In Monday's Mid-Day Session
Gainers Del Taco Restaurants, Inc. (NASDAQ: TACO) shares jumped 64.6% to $12.40. Jack In The Box Inc (NASDAQ: JACK) agreed to acquire Del Taco Restaurants for $12.51 per share... 
Via Benzinga
Dow Extends Rebound as Omicron Fears Subside
The Dow Jones Industrial Average is gaining even more momentum off this morning's bounce, the S&P 500 is also eyeing a strong rally. The Nasdaq Composite (IXIC), on the other hand, has turned... 
Via Talk Markets
Topics Stocks
Mid-Morning Market Update: Markets Mostly Higher; Science Applications International Posts Upbeat Earnings
Following the market opening Monday, the Dow traded up 1.35% to 35,048.01 while the NASDAQ fell 0.17% to 15,059.43. The S&P also rose, gaining 0.59% to 4,565.21. The U.S. has... 
Via Benzinga
Topics Stocks
Bolt Biotherapeutics Reveals Early Data From BDC-1001 Immuno-Oncology Candidate
Bolt Biotherapeutics Inc (NASDAQ: BOLT) announced the presentation of interim clinical data from its Phase 1/2 study of BDC-1001. BDC-1001 is an immune-stimulating... 
Via Benzinga
Innovent Biologics, Bolt Join Forces To Develop Anti-Cancer Candidates
Innovent Biologics Inc (OTC: IVBIY) and Bolt Biotherapeutics Inc (NASDAQ: BOLT) have entered into a drug research and development collaboration for oncology candidates. The... 
Via Benzinga
The Week Ahead In Biotech (Dec. 6-Dec. 11): Daré FDA Decision, Adcom Tryst For Reata, Multiple Conference Presentations And More
The omicron variant concerns were front and center in the markets in the week ended Dec. 3, and biotech stocks did not escape the brunt of selling in the wake of the negative... 
Via Benzinga
The Daily Biotech Pulse: MorphoSys-Incyte Snag European Nod, Immutep Granted Chinese Patent, Bolt Biotherapeutics Strike Oncology Collaboration
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 26) Agenus Inc. (NASDAQ: AGEN)... 
Via Benzinga
Topics Intellectual Property
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS